// App-Quantinova.ai

: THREE-YEAR ANALYSIS OF THE DALIAH TRIAL - A RANDOMIZED CONTROLLED PHASE III CLINICAL TRIAL COMPARING RECOMBINANT INTERFERON ALPHA-2 VS. HYDROXYUREA IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

Researchers

Presenter

  • Trine Alma Knudsen

Principal Investigators

  • Lucas Frans Ocias

  • Ole Weis Bjerrum

  • Mette Brabrand

  • Christina Ellervik

  • Daniel el Fassi

  • Mikael Frederiksen

  • Lasse Kjr

  • Thomas Kielsgaard

  • Torben A. Kruse

  • Hans Torben Mourits-Andersen

  • Peter Mller

  • Ulrik Malthe Overgaard

  • Dustin Andersen Patel

  • Marianne Tang Severinsen

  • Vibe Skov

  • Anders Lindholm Srensen

  • Jesper Stentoft

  • Jrn Starklint

  • Karin de Stricker

  • Mads Thomassen

  • Thomas Stauffer Larsen

  • Hans Hasselbalch

Medical Centers

  • Hematology, Roskilde University Hospital, Roskilde, Denmark

  • Department of Oncology, Odense University Hospital, Odense, Denmark

  • Department of Oncology 5073 Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark

  • Harvard Medical School, Boston, MA, United States

  • Department of Oncology, Odense University Hospital, Odense, Denmark

  • Department of Haematology,Hospital of Southern Jutland,Aabenraa,Denmark

  • Department of Oncology, Odense University Hospital, Odense, Denmark

  • Department of Oncology, Odense University Hospital, Odense, Denmark

  • Department of Haematology,Hospital of Southern Jutland,Aabenraa,Denmark

  • Department of Oncology, Aalborg University Hospital, Aalborg, Denmark

  • Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

  • Department of Haematology,Regional Hospital West Jutland,Holstebro,Denmark

Locations

  • Denmark

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

Disease

  • Myeloid neoplasms

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Interferon alpha

  • Hydroxyurea

  • Hydroxycarbamide

  • Interferon

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT01387763

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved